中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2014年
17期
82-84
,共3页
地屈孕酮%黄体酮%β-HCG%反复性流产%不良反应
地屈孕酮%黃體酮%β-HCG%反複性流產%不良反應
지굴잉동%황체동%β-HCG%반복성유산%불량반응
Dydrogesterone%Progesterone%β-HCG%Recurrent spontaneous abortion%Adverse reaction
目的：分析地屈孕酮与β-HCG联合治疗原因未明反复性流产患者的临床效果。方法选取2011年8月~2012年11月本院收治的原因未明反复性早期流产患者90例为研究对象，并将其随机分成两组，45例患者以黄体酮治疗(黄体酮组)，45例患者以地屈孕酮与β-HCG联合施治(联合治疗组)，另取同期正常孕妇45例为对照组。对比分析3组受试者的血清P、E2、HCG水平，同时比较其妊娠结局与临床不良反应情况。结果孕8周内，黄体酮组与联合治疗组患者的血清P、E2、HCG水平差异无统计学意义(P>0.05)，但均明显低于对照组(P<0.05)；孕9~12周，黄体酮组各项指标明显低于联合治疗组(P<0.05)，联合治疗组患者的各项指标则接近于对照组(P>0.05)。黄体酮组的流产率、不良反应率、新生儿畸形率明显高于联合治疗组(P<0.05)，足月分娩率明显低于联合治疗组(P<0.05)。联合治疗组的妊娠结局和临床不良反应情况与对照组差异无统计学意义(P>0.05)。结论相比于黄体酮治疗，地屈孕酮与β-HCG联合治疗原因未明反复性流产患者的效果更佳，患者各项指标均趋于正常，且妊娠结局与临床不良反应更优。
目的：分析地屈孕酮與β-HCG聯閤治療原因未明反複性流產患者的臨床效果。方法選取2011年8月~2012年11月本院收治的原因未明反複性早期流產患者90例為研究對象，併將其隨機分成兩組，45例患者以黃體酮治療(黃體酮組)，45例患者以地屈孕酮與β-HCG聯閤施治(聯閤治療組)，另取同期正常孕婦45例為對照組。對比分析3組受試者的血清P、E2、HCG水平，同時比較其妊娠結跼與臨床不良反應情況。結果孕8週內，黃體酮組與聯閤治療組患者的血清P、E2、HCG水平差異無統計學意義(P>0.05)，但均明顯低于對照組(P<0.05)；孕9~12週，黃體酮組各項指標明顯低于聯閤治療組(P<0.05)，聯閤治療組患者的各項指標則接近于對照組(P>0.05)。黃體酮組的流產率、不良反應率、新生兒畸形率明顯高于聯閤治療組(P<0.05)，足月分娩率明顯低于聯閤治療組(P<0.05)。聯閤治療組的妊娠結跼和臨床不良反應情況與對照組差異無統計學意義(P>0.05)。結論相比于黃體酮治療，地屈孕酮與β-HCG聯閤治療原因未明反複性流產患者的效果更佳，患者各項指標均趨于正常，且妊娠結跼與臨床不良反應更優。
목적：분석지굴잉동여β-HCG연합치료원인미명반복성유산환자적림상효과。방법선취2011년8월~2012년11월본원수치적원인미명반복성조기유산환자90례위연구대상，병장기수궤분성량조，45례환자이황체동치료(황체동조)，45례환자이지굴잉동여β-HCG연합시치(연합치료조)，령취동기정상잉부45례위대조조。대비분석3조수시자적혈청P、E2、HCG수평，동시비교기임신결국여림상불량반응정황。결과잉8주내，황체동조여연합치료조환자적혈청P、E2、HCG수평차이무통계학의의(P>0.05)，단균명현저우대조조(P<0.05)；잉9~12주，황체동조각항지표명현저우연합치료조(P<0.05)，연합치료조환자적각항지표칙접근우대조조(P>0.05)。황체동조적유산솔、불량반응솔、신생인기형솔명현고우연합치료조(P<0.05)，족월분면솔명현저우연합치료조(P<0.05)。연합치료조적임신결국화림상불량반응정황여대조조차이무통계학의의(P>0.05)。결론상비우황체동치료，지굴잉동여β-HCG연합치료원인미명반복성유산환자적효과경가，환자각항지표균추우정상，차임신결국여림상불량반응경우。
Objective To analyze the clinical therapeutic effects of dydrogesterone in combination withβ-HCG on un-explained recurrent spontaneous abortion (RSA). Methods A total of 90 early RSA patients admitted to our hospital from August 2011 to November 2012 were selected as subjects,who were randomly divided into two groups,with 45 cas-es receiving progesterone for treatment (progesterone group) and 45 cases receiving dydrogesterone in combination withβ-HCG for treatment (combination therapy group),another 45 concurrent normal pregnant women were selected as the control group.The serum P,E2 and HCG of patients in three groups were detected and compared,followed by comparison of pregnancy outcomes and adverse reactions. Results Within 8 gestational weeks,the serum P,E2 and HCG of the pro-gesterone group and combination therapy group showed no significant difference (P>0.05),but were lower than those of the control group (P<0.05),during 9-12 gestational weeks,all the indicators of the progesterone group were significantly lower than those of the combination therapy group (P<0.05),and the indicators of the combination therapy group were close to those of the control group (P>0.05).The abortion rate,adverse reaction rate and birth defect rate of the proges-terone group were significantly higher than those of the combination therapy group (P<0.05),and the term birth rate of the progesterone group was lower than that of the combination therapy group (P<0.05).There was no significant differ-ence in pregnancy outcomes and adverse reactions between the combination therapy group and the control group (P>0.05). Conclusion Compared with progesterone treatment, the combination therapy by dydrogesterone and β-HCG has better effects on unexplained RSA,which can return indicators of patients to the normal level with better pregnancy out-comes and less adverse reactions.
